JNJ240920C125000
- 40.15
- 0.000.00%
Johnson & Johnson Newsroom
RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $175
Johnson & Johnson (JNJ) Gets a Buy From RBC Capital
Johnson & Johnson Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Cantor Fitzgerald Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $215
Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating
Johnson & Johnson Analyst Ratings
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating
Johnson & Johnson Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Cantor Fitzgerald Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $215
Cantor Fitzgerald Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $215
The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $169
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Johnson & Johnson Analyst Ratings
Cantor Fitzgerald Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $215
Johnson & Johnson Price Target Maintained With a $215.00/Share by Cantor Fitzgerald